RxDoctor Payments Data

Kerry Rhodes, MD

Family Medicine · Austin, TXNPI 1083697593

Payments from drug & device makers

$15,546in general payments, 2019–2025

Across 954 payments — averaging $16.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$2K
  • Lilly USA, LLC$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$800
  • Boehringer Ingelheim$733
  • Kowa Pharmaceuticals America, Inc.$723
  • plus $8K from 54 others

What the payments were for

  • Food & beverage$15,486100%
  • Gifts$590%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)138$2,086
Novo Nordisk123$1,821
Lilly USA, LLC103$1,432
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC55$800
Boehringer Ingelheim41$733
Kowa Pharmaceuticals America, Inc.46$723
AstraZeneca38$706
Takeda Pharmaceuticals U.S.A., Inc.52$580
Amgen27$509
Johnson & Johnson30$473
Pfizer24$438
GSK29$407
Otsuka America Pharmaceutical, Inc.20$380
Eisai Inc.13$363
Bausch Health US, LLC12$342
Arbor Pharmaceuticals, Inc.19$292
Amarin Pharma, Inc.12$218
Astellas Pharma US Inc13$218
Exact Sciences14$202
Lundbeck LLC9$199
Abbott8$187
Biosense Webster, Inc.6$172
Gilead10$157
Shockwave Medical, Inc1$148
Azurity Pharmaceuticals, Inc.9$148
Biohaven Pharmaceutical Holding Company Ltd.22$139
Abiomed1$131
Supernus Pharmaceuticals, Inc.4$128
Idorsia Pharmaceuticals US Inc6$104
Mannkind Corporation3$87
IBSA Pharma Inc.6$86
Novartis5$85
Impulse Dynamics (USA) Inc.1$80
Genentech USA, Inc.5$75
Corcept Therapeutics3$74
Biohaven Pharmaceuticals, Inc.4$66
Teva Pharmaceuticals USA, Inc.3$61
Esperion Therapeutics, Inc.4$54
Convatec Inc.2$54
Amneal Pharmaceuticals LLC3$51
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)2$48
Bayer2$41
Ardelyx, Inc.2$41
Acerus Pharmaceuticals Corporation2$34
Medicure Pharma Inc.1$31
Alk-abello, Inc1$31
Adlon Therapeutics L.p.2$30
Currax Pharmaceuticals LLC2$28
Circassia Inc.2$26
Globus Medical1$24
Althera Pharmaceuticals LLC3$23
Dexcom, Inc.1$23
Hikma Pharmaceuticals USA1$22
Tolmar, Inc.1$22
Ironshore Pharmaceuticals Inc.1$22
Ironwood Pharmaceuticals, Inc1$19
Shield Therapeutics Inc1$19
Aytu Biopharma, Inc.1$17
Nevro Corp.1$13
Upsher-smith Laboratories LLC1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,546 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$48,266
Medicare patients
144
Services billed
515

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide36$53,233
MounjaroTirzepatide40$41,133
FarxigaDapagliflozin Propanediol40$34,137
JardianceEmpagliflozin41$29,663
RybelsusSemaglutide15$20,573
LivaloPitavastatin Calcium36$19,708
EliquisApixaban12$19,253
JanuviaSitagliptin Phosphate11$11,454
TrulicityDulaglutide12$9,108
VascepaIcosapent Ethyl13$7,266
Bevespi AerosphereGlycopyrrolate/Formoterol Fum12$4,688
SynthroidLevothyroxine Sodium49$4,336
VyvanseLisdexamfetamine Dimesylate11$4,047
Dexlansoprazole DrDexlansoprazole16$3,465
Rosuvastatin Calcium324$3,088

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,821$73,80751 claims
Lilly USA, LLCMounjaro, Trulicity$1,432$50,24052 claims
AstraZenecaFarxiga, Bevespi Aerosphere$706$38,82552 claims
Boehringer IngelheimJardiance$733$29,66341 claims
Kowa Pharmaceuticals America, Inc.Livalo$723$19,70836 claims
PfizerEliquis$438$19,25312 claims
AbbVieSynthroid$2,086$4,33649 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$580$4,04711 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$51$1,22085 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Austin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →